Product
BMS-936558
1 clinical trial
1 indication
Indication
Hematologic NeoplasmsClinical trial
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (Relatlimab, BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Relapsed or Refractory B-Cell MalignanciesStatus: Completed, Estimated PCD: 2022-02-16